Viral Vector

Bringing Excellence in Manufacturing & Quality to the Rapidly Growing Cell and Gene Therapy Market

An image showing a facility employee working with bioreactors at Avid Bioservices' new viral vector & adenovirus manufacturing facility in California, USA
An external image of the Avid Bioservices viral vector manufacturing facility in California, USA
Investing $75 Million into the future of Cell & Gene Therapy

We are expanding our CDMO service offering into the rapidly growing cell and gene therapy market. 

The company is constructing a world-class, purpose-built 53,000 sq. ft. viral vector development and CGMP manufacturing facility in Costa Mesa, CA.

Purpose-Built Viral Vector Facility

World-Class Viral Vector Development and Manufacturing Facility Being Built in Orange County, CA

  • Located in Costa Mesa, California approximately 5 miles from our existing campus
  • State of the Art Process Development and Quality Control Laboratory Space
  • World Class CGMP Manufacturing Space for Viral Vectors

 

MEET OUR NEW HEAD OF TECHNOLOGY

Elie Hanania, Ph.D.

  • 30+ years of experience in the cell & gene therapy field
  • 15+ years of experience in the CDMO sector
  • Subject matter expert in process development for viral vector production, purification, & characterization
  • Extensive experience with a wide selection of viral vector products

Process Development

  • Experience with Various Vector Types
    • AAV, Lentiviral Vector, Adenoviral Vector
  • Offering a Wide Range of Viral Vector Characterization Assays
  • Develop and/or Tech Transfer:
    • Client-Specific Assays
    • Viral Vector Production
    • Viral Vector Purification
    • Generation of Bulk Drug Substance
  • Optimize and Transfer Processes to CGMP Manufacturing
  • Optimize and Transfer Analytical Assays to Quality Control
  • Site-Wide Support for Client-Related Viral Vector Programs

CGMP Viral Vector Manufacturing

  • CGMP Cell & Viral Banking
  • Bioreactor Capacity
    • A Train
      • Capable of up to 250L suspension culture or multi-layer single use vessels for adherent culture
    • B Train
      • Capable of up to 3,000L suspension culture or large scale adherent fixed bed bioreactors
  • Semi-Automated Fill & Finish Capabilities
  • QA Product Release Testing

Viral vector production and manufacturing experience

Upcoming Events:

Meet us May 16th – 19th, 2022 in Washington DC at ASGCT 25th Annual Meeting

Meet us June 13th – 16th, 2022 in San Diego, CA at BIO International Convention

Click here for an exclusive interview with our General Manager of Viral Vector Technologies, Drew Brennan

Close this popup.
We use cookies to improve your experience on our site. To find out more, read our Privacy Policy.